Cannabidiol is under clinical development by EmpowerPharm and currently in Phase II for Social Anxiety Disorder (SAD/Social Phobia). According to GlobalData, Phase II drugs for Social Anxiety Disorder (SAD/Social Phobia) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Cannabidiol LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cannabidiol overview

Cannabidiol is under development for the treatment of social anxiety disorders. It is administered through oral route as a tablet and solution. It acts by targeting CB1 and CB2 receptors.

EmpowerPharm overview

EmpowerPharm is an early-stage pharmaceutical company that developing prescription CBD tablets for anxiety sufferers. The company is headquartered in Toronto, Ontario, Canada.

For a complete picture of Cannabidiol’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.